生命科学资讯

Drugmakers with White House pricing deals may skirt new Medicare demos

Gilead's herpes deal; FDA approvals for Boehringer, Roche

Labcorp backs Cellens in developing physics test aimed at bladder cancer

Neurocrine’s Ingrezza flunks pivotal study in dyskinetic cerebral palsy

Updated: Pfizer discloses patient death in Hympavzi hemophilia trial

Novo Nordisk eyes a strong launch with FDA approval of obesity pill

CMS proposes two long-awaited Medicare drug pricing demos

China's new commercial insurance model could broaden access to Alzheimer's drugs

Bristol Myers brings IRA drug pricing fight to Supreme Court

US charges six people with insider trading in case including Olema Oncology

Windward gets bispecific from Qyuns in its second China deal of the year

Shionogi will pay $2.5B to acquire one of the only approved ALS drugs

Ipsen gains access to ADC from Shanghai biotech Simcere Zaiming

Boehringer taps Rectify to create pills for chronic kidney disease

AstraZeneca bets up to $2B on Jacobio’s pan-KRAS inhibitor for cancer

Aktis Oncology files for IPO to fund Lilly-partnered radiopharma pipeline

Nine more MFN deals; Western drugmakers turn to China; Chai Discovery's raise; and more

FDA approves Cytokinetics’ heart drug, giving it an edge over BMS rival

White House unveils nine new ‘most favored nation’ deals

Galapagos' last asset posts mixed results as future remains in flux